Generation Bio

215 First Street
Cambridge
Massachusetts
02142
United States

About Generation Bio

Generation Bio is a biotechnology company developing a breakthrough class of genetic medicines to enable a new generation of people unaffected by inherited disease. The company’s therapies are based on its proprietary GeneWave™ technology, which delivers durable, high levels of gene expression and can be re-dosed to titrate to effect and to sustain impact over a lifetime. Generation Bio was founded and launched by Atlas Venture, and is headquartered in Cambridge, Mass.

YEAR FOUNDED:
2016

LEADERSHIP:
Founder & COO: Mark Angelino
President & CEO: Geoffrey McDonough
CFO: Glenn Goddard
Head of Preclinical Research and Clinical Development: Doug Kerr

54 articles with Generation Bio

Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results

8/4/2022

Generation Bio Co., a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and second quarter 2022 financial results.
Generation Bio to Present at the 2022 Wedbush PacGrow Healthcare Conference

8/2/2022

Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a panel at the virtual 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9th at 9:45 a.m. ET.
Generation Bio Appoints Dannielle Appelhans to Its Board of Directors

7/18/2022

Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Dannielle Appelhans has been appointed to its Board of Directors. Dannielle Appelhans is a tenured pharmaceutical executive who has built deep expertise in strategy, manufacturing, supply chain and operations.
Generation Bio Announces Update to Its GMP Manufacturing Strategy

6/21/2022

Company projects smaller GMP manufacturing footprint, enabled by further process development of rapid enzymatic synthesis of ceDNA at scale Company will seek to sublease its planned GMP facility, and will adopt a more capital efficient, modular, and flexible manufacturing approach Capital reallocated from facility buildout expected to extend cash runway into 2025.
Generation Bio to Present at the 2022 Jefferies Healthcare Conference

6/2/2022

Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 2022 Jefferies Healthcare Conference on Friday, June 10th at 11:00 a.m. ET in New York.
Generation Bio Reports Business Highlights and First Quarter 2022 Financial Results

5/5/2022

Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and first quarter 2022 financial results.
Generation Bio to Participate in 21st Annual Needham Virtual Healthcare Conference

4/5/2022

Generation Bio Co. announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11th at 11:00 a.m. ET.
Generation Bio to Participate in 42nd Annual Cowen Health Care Conference

3/2/2022

Generation Bio Co. announced that Geoff McDonough, M.D., president and chief executive officer, will participate in the Gene Therapy panel discussion at the 42nd Annual Cowen Health Care Conference on Wednesday, March 9 at 12:50 p.m. ET.
Generation Bio Outlines 2022 Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results

2/24/2022

Generation Bio Co., a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, outlined its strategic priorities for 2022 and reported fourth quarter and full year 2021 financial results.
BioSpace Movers & Shakers, Feb. 11

2/11/2022

Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
Generation Bio Promotes Antoinette Paone, M.S., MBA to Chief Operating Officer

2/10/2022

Generation Bio Co. announced the promotion of Antoinette Paone to chief operating officer (COO).
Generation Bio to Present at 40th Annual J.P. Morgan Healthcare Conference

1/5/2022

Generation Bio Co. announced today that the company will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12, 2022.
It's Back to the Drawing Board for Generation Bio’s Hemophilia A Program

12/15/2021

Generation Bio’s stock plummeted 54% to $6.35 yesterday after it reported in an SEC filing that its hemophilia A therapy data in mice couldn’t be duplicated in non-human primate studies.
Generation Bio Provides Update on Preclinical Studies for Hemophilia A Program

12/14/2021

Generation Bio Co. today provided an update on factor VIII expression from a series of mouse and companion non-human primate (NHP) studies in hemophilia A, as well as an update on the development of its non-viral genetic medicine platform.
Generation Bio Reports Business Highlights and Third Quarter 2021 Financial Results

11/10/2021

Generation Bio Co reported recent business highlights and third quarter 2021 financial results.
Generation Bio Presents Data Demonstrating First Lipid Nanoparticle to Achieve Uniform Retinal Transduction and Tolerability via Sub-Retinal Delivery of ceDNA and mRNA at the European Society of Gene and Cell Therapy 2021 Annual Virtual Congress

10/22/2021

Generation Bio Co. today presented new preclinical data demonstrating widespread delivery of multiple nucleic acid cargos to photoreceptors using the company’s cell-targeted lipid nanoparticle (ctLNP).
Generation Bio to Present at Jefferies Virtual Gene Therapy/Editing Summit

10/21/2021

Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Virtual Gene Therapy/Editing Summit on Wednesday, October 27 at 5:00 p.m. ET.
Generation Bio to Present at Wedbush PacGrow Healthcare Conference 2021

8/3/2021

Generation Bio Co. announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a panel discussion at the Wedbush PacGrow Healthcare Conference 2021 on Tuesday, August 10 at 9:10 a.m. ET.
Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Provides Pipeline Update

7/14/2021

Company to transition all portfolio programs to rapid enzymatic synthesis (RES), enabling improved quality, scale and speed of closed-ended DNA manufacturing
Generation Bio to Present at William Blair Biotech Focus Conference

7/8/2021

Generation Bio Co. announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, at 9:00 a.m. ET.